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ABSTRACT
Introduction: To explore the relationship of
pain and fatigue with daily activity and work
productivity in rheumatoid arthritis (RA)
patients from the baricitinib clinical trial, RA-
BEAM.
Methods: In RA-BEAM, a double-blind phase 3
study, patients were randomized 3:3:2 to
placebo (n = 488), baricitinib 4 mg once daily
(n = 487), or adalimumab 40 mg biweekly
(n = 330) with background methotrexate. The
Functional Assessment of Chronic Illness Ther-
apy-Fatigue (FACIT-F) measured fatigue and the
pain visual analog scale (0–100 mm) assessed
pain. Work Productivity and Activity Impair-
ment Questionnaire-RA measured daily activity
and work productivity. At weeks 12 and 24, pain
was assessed using pain reduction (\ 30%, 30%
to\50%, C 50%) and overall pain score; clini-
cally relevant FACIT-F changes were assessed by
values\ 3.56 and C 3.56 and the FACIT-F nor-
mative value score (\ 40.1, C 40.1). Pairwise
comparisons between pain/fatigue reduction
groups were assessed using ANCOVA with
pooled data on daily activity and work produc-
tivity. A mediator analysis with pain, fatigue,
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and disease activity measured their contribu-
tion to daily activity and work productivity.
Data were pooled from all patients for most
analyses, and baricitinib-treated patients were
assessed as a sensitivity analysis.
Results: Reductions in pain (C 50%) and fati-
gue (C 3.56) had significant (p B 0.001) effects
on daily activity and work productivity
improvement at weeks 12 and 24. Reductions in
pain, fatigue, and disease activity accounted for
most of the improvements in daily activity and
work productivity. At the lowest levels of
remaining pain (B 10 mm) at weeks 12 and 24,
however, fatigue did not appear to impact work
productivity. Similar trends were observed with
baricitinib-treated patients.
Conclusions: Reductions in pain and fatigue
were associated with improved daily activity
and work productivity for all RA patients and
for baricitinib-treated patients in RA-BEAM.
Trial Registration: ClinicalTrials.gov identifier,
NCT01710358.
Funding: Incyte Corporation and Eli Lilly and
Company.
Keywords: Baricitinib; Health-related quality
of life; Patient-reported outcomes; Work
impairment
INTRODUCTION
Patients rank ability to work as an important
treatment outcome because it affects income,
living conditions, quality of life (QOL), and the
ability to maintain independence [1, 2]. After
the onset of rheumatoid arthritis (RA), a large
percentage of patients with RA report impair-
ment in their daily activity and increased issues
with presenteeism and absenteeism before their
early departure from the work force [3, 4]. It is
estimated that work disability for patients with
RA is twice that of the general population [4].
With new therapies for RA, there is an
increased interest in controlling disease and
improving patients’ health-related QOL that
will enable patients to function in social and
work settings [4]. Patients with RA indicate that
pain and fatigue are common and burdensome
symptoms of their disease [2], yet it is not clear
how much pain and fatigue, evaluated individ-
ually and together, impact other aspects of life,
such as work productivity.
The purpose of our analysis was to explore
the relationship between pain and fatigue with
daily activity and work productivity, in patients
from a randomized, double-blind, phase 3
clinical trial of baricitinib, an oral, selective
inhibitor of Janus kinase (JAK)1 and JAK2 [5].
METHODS
Patients
This is a post hoc analysis of the baricitinib
clinical trial, RA-BEAM (NCT01710358), in
which baricitinib 4 mg plus methotrexate
(MTX) was associated with significant clinical
improvements, including pain and fatigue, over
MTX plus adalimumab [6, 7]. The RA-BEAM
study was approved by Quorum Review IRB
#27257. Additionally, each participating cen-
ter’s institutional review board or ethics com-
mittee approved the study. The list of centers
can be found in the first RA-BEAM publication.
The study was conducted in accordance with
ethical principles of the Declaration of Helsinki
and Good Clinical Practice guidelines. All
patients provided written informed consent. No
additional ethical approval was required to
conduct the current post hoc analysis. Results
from the study have been published previously
[6, 7]. Briefly, the trial was a randomized, dou-
ble-blind, double-dummy, placebo-controlled
and active-controlled, parallel-arm, 52-week
study. Patients (n = 1,305) on stable background
MTX were randomly allocated (3:2:3) to pla-
cebo, 40 mg of subcutaneous adalimumab every
other week, or 4 mg of baricitinib orally daily.
Patients were C 18 years old with active RA
[C 6/68 tender and C 6/66 swollen joints;
C-reactive protein (CRP) C 6 mg/l]. Patients had
an inadequate response to MTX and were
required to have either C 3 joint erosions (based
on radiographs) or[1 joint erosion and be
seropositive for rheumatoid factor or anti-
citrullinated peptide antibodies [7].
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Measures
Pain was measured on a visual analogue scale
(VAS), with responses ranging from 0 mm (no
pain) to 100 mm (worst possible pain). The pain
VAS was administered at all study visits.
Reduction in pain was categorized as\30%,
30% to\50%, C 50% pain relief at weeks 12
and 24. These thresholds were chosen based on
the recommendations by the Initiative on
Methods, Measurement, and Pain Assessment in
Clinical Trials, a group focusing on improve-
ments of clinical studies in chronic pain con-
ditions [8]. Likewise, remaining pain was
assessed and categorized as B 10 mm,[10
to B 20 mm,[20 to B 40 mm,[40 mm. The
10 mm threshold was derived from data by
Wells, et al. [9]; the 20 mm threshold reflects
when pain does not negatively affect health-
related QOL [9, 10]; and the 40 mm threshold
was based on cut-off points between the pain
VAS and the Patient Acceptable Symptom State
(PASS) [11].
Fatigue was assessed using the Functional
Assessment of Chronic Illness Therapy-Fatigue
(FACIT-F) scale, with a range from 0 to 52, with
higher scores representing less fatigue [12]. A
normative score for the FACIT-F is C 40.1 and
the minimum clinically important difference
(MCID) value of 3.56 was used to assess the
clinical relevance of changes in the FACIT-F
[12–14]. The FACIT-F was administered at
baseline, week 4, and every 4 weeks thereafter
until week 32, and then at week 40 and week 52.
At weeks 12 and 24, the following were evalu-
ated: the percentage of patients reporting
improvement in fatigue (\3.56, C 3.56) and
the percentage of patients reporting FACIT-F
normative values (C 40.1) or not (\40.1).
The Work Productivity Impairment Ques-
tionnaire-Rheumatoid Arthritis (WPAI-RA)
measured work and activity impairments over
the past 7 days. The instrument is composed of
six questions that are calculated into four
scores: normal daily activities (daily activity
impairment), work-time missed due to RA (ab-
senteeism), impairment while working due to
RA (presenteeism), and overall work impair-
ment due to RA (work productivity impair-
ment). Scores are the percentages of impairment
(0–100%), with higher scores denoting greater
impairment [15]. The WPAI-RA was adminis-
tered at baseline, week 2, week 4, and then fol-
lowed the same schedule as the FACIT-F at later
study visits. The current analysis focused on
impairment of daily activity and of work pro-
ductivity. Absenteeism and presenteeism,
which are used to calculate work productivity
impairment, are presented in the Data
Supplement.
Additional Variables
In addition to pain and fatigue, we assessed the
relationship between CRP, tender joint count
(TJC), and swollen joint count (SJC) with the
scores from the WPAI-RA.
Statistical Analyses
Data were pooled across treatment arms for
analyses assessing correlation between variables
described below and the relationship between
pain, fatigue, and the WPAI-RA. Data from
baricitinib-treated patients were analyzed alone
as a sensitivity analysis and are included in the
Data Supplement. Missing values were imputed
using the modified last-observation carried for-
ward method.
Spearman correlations were assessed with the
change from baseline for pain VAS, FACIT-F,
and other variables (CRP, SJC28, TJC28) with
the WPAI-RA scores using observed data at
weeks 12 and 24. This assessment was con-
ducted to determine which factors were more
correlated with impairments in daily activity
and work productivity. Spearman correla-
tions B 0.40 were considered low correlation,
0.41 to B 0.75 were moderate correlation,
and[ 0.75 were strong correlation [16].
Pairwise comparisons of improvement in
WPAI-RA scores between pain (\30%, 30 to
\50%, and C 50%) and between fatigue
reduction groups (\3.56 and C 3.56) at weeks
12 and 24 were assessed by ANCOVA adjusting
for geographical region, baseline joint erosion
status, and baseline values of WPAI-RA scores.
Because pain, fatigue, and disease activity,
defined by Disease Activity Score 28-joint
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count-CRP (DAS28-CRP), may impact daily
activity and work productivity, we conducted a
mediation analysis to assess their relative con-
tribution to improvements in daily activity and
work productivity by treatment over placebo at
weeks 12 and 24 [17]. In the mediation analysis,
the dependent variable was the improvement
from baseline to week 12 or 24 for daily activity
or work productivity. The treatment (baricitinib
vs. placebo or adalimumab vs. placebo) was the
independent variable. Changes in pain, fatigue,
and DAS28-CRP from baseline to week 12 or
week 24 were used as the mediator variables.
The total treatment effect on daily activity or
work productivity over placebo that can be
accounted for by changes in pain, fatigue, and
DAS28-CRP is the ‘‘indirect’’ or mediation effect;
whereas, the total treatment effect that cannot
be accounted for by the mediation effect is the
‘‘direct’’ effect (Figure S1).
Statistical analyses were performed with SAS
(SAS Institute; Cary, NC, version 9.4). A two-
sided p value\ 0.05 was considered statistically
significant. P-values were not adjusted for mul-
tiple comparisons.
RESULTS
Baseline Patient Characteristics
The baseline patient characteristics were similar
across treatment groups [6, 7]. The majority of
patients were women with a mean age of
approximately 53 years. Most patients included
in the trial had long disease duration, with a
time from RA diagnosis of approximately
9 years. For the WPAI-RA at baseline, 545
patients (42%) were employed. Across treat-
ment groups, the mean baseline values ranged
from 56 to 58% for impairment in daily activi-
ties, 12–13% for absenteeism, 42–46% for pre-
senteeism, and 45–49% for work productivity
impairment (Table S1, Table 2).
Correlation Analyses
When all the patient data were combined, cor-
relation analyses indicated statistically
significant correlations between reductions in
pain and fatigue with improvements in daily
activity and work productivity at both week 12
and 24 (Table 1). Specifically, the correlation (R
values) for pain and fatigue ranged from 0.4 to
0.5 (moderate correlation); whereas the corre-
lation values for CRP, SJC28, and TJC28 ranged
from 0.1 to 0.3 (low correlation). Similar results
were observed for baricitinib-treated patients
(Table S3).
Table 1 Spearman correlation between pain, fatigue,
CRP, SJC28, and TJC28 with impairment in daily activity
and work productivity
Timepoint Change in
daily activity
Change in work
productivity
Change in pain VAS
Week 12 0.51*** 0.43***
Week 24 0.53*** 0.41***
Change in FACIT-F total score
Week 12 - 0.48*** - 0.46***
Week 24 - 0.47*** - 0.38***
Change in CRP
Week 12 0.20*** 0.19***
Week 24 0.15*** 0.13*
Change in SJC28
Week 12 0.23*** 0.17***
Week 24 0.19*** 0.15**
Change in TJC28
Week 12 0.32*** 0.29***
Week 24 0.26*** 0.22***
*p B 0.05, ***p B 0.001; Spearman correlation values
from approximately 0.4–0.5 indicate moderate correlation;
whereas the correlation values from 0.1 to 0.3 indicate low
correlation [16]
CRP C-reactive protein, FACIT-F functional assessment
of chronic illness therapy-fatigue, SJC28 swollen joint
count-28, TJC28 tender joint count-28, VAS visual analog
scale
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Treatment Effect upon Pain, Fatigue,
and WPAI-RA at Weeks 12 and 24
At week 12, patients treated with baricitinib and
adalimumab reported statistically significantly
greater improvements from baseline for both
pain and fatigue compared with placebo-treated
patients (p B 0.001) [6] (Table 2). For pain, the
change from baseline was greater for baricitinib-
treated compared with adalimumab-treated
patients (p B 0.01). Likewise, at week 12,
patients treated with baricitinib or adalimumab
reported improvements in their daily activity.
Baricitinib-treated patients reported improve-
ment in work productivity compared with pla-
cebo; in contrast, there were no statistically
significant differences for adalimumab com-
pared with placebo (Table 2). Similar trends
were observed at week 24 (Table 2).
Association of Pain and Fatigue with Daily
Activity and Work Productivity
For all patients combined at week 12, patients
with C 50% reduction in pain from baseline
had significantly greater improvements (p
B 0.001) in daily activity and work productivity
compared to those with less reduction in pain
(Fig. 1). At week 24, patients with C 50%
reduction in pain from baseline reported sta-
tistically significant improvements (p B 0.001)
only in daily activity compared to those with
less pain reduction. Similar findings were
observed for baricitinib-treated patients at
weeks 12 and 24 (Figure S3).
At weeks 12 and 24, patients who had a
clinically relevant change in fatigue, a FACIT-F
MCID of C 3.56 from baseline, also experienced
significantly greater improvements in daily
activity and work productivity compared to
those who did not achieve the MCID (Fig. 1).
Similar results were observed among baricitinib-
treated patients (Fig. 1, Figure S5).
At weeks 12 and 24, those patients who
reported values that met or exceeded the ‘‘nor-
mal’’ value of fatigue (FACIT-F C 40.1) and the
lowest levels of remaining pain (pain
VAS B 10 mm), reported approximately 30%
improvement in daily activities (Fig. 2). For
each increasing level of remaining pain,
improvement in daily activity decreased. Addi-
tionally, patients with less fatigue tended to
report greater improvement in daily activity
compared to those who reported more fatigue.
At the lowest levels of remaining pain
(B 10 mm), fatigue did not appear to affect
work productivity. For example, at week 12,
among patients with minimal remaining pain
(B 10 mm), the percentage of improvement in
work productivity was 26% and 31% for those
with low (C 40.1) and higher (\40.1) levels of
fatigue, respectively. With increasing levels of
pain ([ 10 mm), levels of fatigue tended to have
a greater relationship with work productivity
improvement (Fig. 2, Figure S5).
Mediator Analysis
The total effect of baricitinib over placebo on
daily activity or work productivity tended to be
greater than that for adalimumab over placebo
at both weeks 12 and 24 (Fig. 3). In the media-
tion analysis, the contributions of pain, fatigue,
and disease activity by treatment on daily
activity or work productivity represented the
combined ‘indirect effect’ or the mediation
effect while the total treatment effect on daily
activity or work productivity that is not
accounted for by the mediation effect is called
‘direct effect’. The mediation effect accounted
for the majority of the total effect (indirect and
direct effect combined) in improvements in
daily activity or work productivity over placebo
at weeks 12 or 24 (Fig. 3).
DISCUSSION
The burden of RA for patients in this trial was
high in terms of baseline impairments in daily
activity and work productivity. Specifically,
across all patients at baseline, the daily activity
impairment was[50%. Of the 545 patients
who were employed at baseline, the work pro-
ductivity impairment ranged from 45 to 49%.
Treatment with baricitinib or adalimumab
resulted in reductions of pain and fatigue and
improvements in daily activity and work pro-
ductivity compared to placebo. In our analyses,
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Fig. 1 a The relationship of pain and fatigue with
improvement in daily activity at weeks 12 and 24.
*p B 0.05, **p B 0.01, ***p B 0.001 vs.\ 30% pain
reduction; p B 0.05, p B 0.01, p B 0.001 vs. 30 to
\ 50% pain reduction. b The relationship of pain and
fatigue with improvement in work productivity at weeks
12 and 24. *p B 0.05, **p B 0.01, ***p B 0.001 vs.\ 30%
pain reduction; p B 0.05, p B 0.01, p B 0.001 vs.
30 to\ 50% pain reduction
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we observed that pain and fatigue tended to be
more correlated with daily activity and work
productivity, compared to other measures, such
as CRP, TJC, and SJC, thus confirming the fea-
sibility of focusing on pain and fatigue as factors
for impairments in daily activity and work
productivity. Pain and fatigue had significant
independent effects on daily activity and work
productivity over 24 weeks of treatment. When
pain and fatigue were evaluated together, we
observed that at the lowest level of remaining
pain, work productivity improvement was not
influenced by fatigue. At higher levels of
remaining pain, however, the data suggested
that both pain and fatigue have an impact on
patient’s work productivity. Reductions in pain
and fatigue, along with low disease activity,
accounted for most of the improvements in
daily activity and work productivity with
treatment.
Our results are consistent with prior studies
that have found that pain and fatigue are con-
tributors to productivity-related outcomes
[18–22]. Our analysis, however, expands upon
prior research by demonstrating the relative
contributions of pain and fatigue.
The current analysis has limitations. Because
the data are derived from a clinical trial in
which patients initially had long disease dura-
tion and high disease activity, the results may
not be generalizable to other RA patients.
Additionally, we did not capture the type of
employment for the patients, which may
influence patient reporting. For example,
patients with RA working in an office setting
may more easily adjust their work day to
accommodate their symptoms compared with
patients in more physically demanding work.
Similarly, we may not have captured other fac-
tors that influence daily activity and work
productivity.
CONCLUSIONS
Results from this analysis indicate that reduc-
tions in pain and fatigue were associated with
improved daily activity and work productivity
in RA regardless of treatment, and greater
Fig. 2 a Pain, fatigue, and improvement in daily activity at
week 12. b Pain, fatigue, and improvement in daily activity
at week 24. c Pain, fatigue, and improvement in work
productivity at week 12. d Pain, fatigue, and improvement
in work productivity at week 24
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reductions resulted in more productivity. If
remaining pain was minimal, however, similar
levels of improvement in work productivity
were observed regardless of fatigue level. These
trends were also observed among baricitinib-
treated patients.
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